No, I am not swing trader. As mentioned i am invested for minimum 3-4 years in most of portfolio stocks. Also i mostly rely on fundamentals, concalls etc. I exit only the tracking positions which i take if am not able to make my mind. Zodiac was tracking position. Phantom will see a lot of disruption to business model thus the exit and IPL was mentioned to be cyclical bet in any case. Other than that ~90% of portfolio remains as it is in last two posts. What makes u feel like i churn a lot?
Troll’s Portfolio (10-10-2024)
Just one thing I have noticed. You seem to change your composition quite frequently. Are you more of a swing trader? If you are seeking investments, then it is important to stay put for a while and only exit if your thesis breaks up.
Warren Wilson, Pioneering Los Angeles TV Reporter, Dies at 90 (10-10-2024)
In addition to covering the 1992 riots and other historically significant events, he helped facilitate the surrenders of 22 fugitives.
Frances Conley, Neurosurgeon Who Protested Sexism, Dies at 83 (10-10-2024)
She was the rare woman in her field, and a tenured professor. But when a sexist colleague was promoted, she quit, forcing a reckoning in her profession.
Hurricane Recovery Efforts Disrupted by Conspiracy Theories and Falsehoods (10-10-2024)
Experts warn that weather-related disinformation can rapidly escalate into real-world risks and distract from aid.
France Unveils Tough Austerity Budget to Mend Its Finances (10-10-2024)
The French government is seeking deep spending cuts and higher taxes in an effort to tame its ballooning debt and deficit.
Lincoln Pharma … the next mid-cap pharma in the making …? (10-10-2024)
Lincoln Pharma has a history of inflating its profits, In FY 2012, the company reported a lower provision for bad debt, categorizing it under trade receivables.
With other income sources including 22 crores from share valuations related to investments or trading.
The company also lends money to Downtown Finance, managed by key personnel who invest in Lincoln Pharma shares during significant stock price declines. When asked about this, Munjal Patel stated, “We help them, and they help us,” emphasizing their reciprocal relationship.
Even after excluding fair valuations from stock trading income, the price-to-earnings ratio stands at 20, and low sales growth since 2016 likely contributes to this low P/E ratio.
[My view] Additionally, being a debt-free company, Lincoln Pharma has the flexibility to take risks and generate capital from various sources, including stock trading, which it can ultimately reinvest in its business. If revenue increases in the near future, the price-to-earnings ratio could rerate to 35 or higher, potentially pushing market capitalization beyond 5,000 crores and positioning it as a potential multibagger.
Moreover, cephalosporin developments are in the final stages and are expected to be monetized soon. According to management, this could boost revenue by 250 crores, serving as a significant growth trigger for the company.
Disc: Invested
NPST – Technology Provider for UPI Tech (10-10-2024)
Good analysis Raj. All the numbers I have quoted are QoQ and not YoY. The 2nd table I have is summation from the 1st table, adding 3 months.
The larger point that I was trying to make (and I see you’re coming to the same conclusion) is that the market seems to assume that the drop in Cosmos Payee PSP numbers will have an equivalent impact on the NPST revenues and eventually the stock price, which I don’t think is going to be the case. It may be directionally right but definitely NOT in terms of quantum.
Lincoln Pharma … the next mid-cap pharma in the making …? (10-10-2024)
If we look at last year, the core profit growth YoY has been at 11% while the net profit growth has been at 22% due to the other income.
However the stock p/e excluding the other income is still around 14 (souce screener). Stock still looks cheap to me. But for a rerating they will need to show growth in core business which they have been promising of 15%+
Market expects RBI to kickstart easing with a shallow cut in December (10-10-2024)
The Reserve Bank of India has shifted to a ‘neutral’ policy stance, increasing expectations of a rate cut in December. Most financial institutions anticipate a 25 basis point cut. Market participants will closely monitor inflation and growth indicators. The RBI’s decision provides flexibility for potential rate easing as inflation remains within legal limits.